SCHEMBL922482

SCHEMBL922482

N#CC(C#N)=NNc1ccc(C(F)(F)F)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.64
MEN1 O00255 10/20 0.64
KMT2A Q03164 10/20 0.64
TDP1 Q9NUW8 7/20 0.64
ALDH1A1 P00352 7/20 0.64
CYP3A4 P08684 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
ALOX15 P16050 2/20 0.64
TSHR P16473 2/20 0.64
HSD17B10 Q99714 2/20 0.64
HIF1A Q16665 2/20 0.64
TP53 P04637 1/20 0.64
BLM P54132 1/20 0.64
EPAS1 Q99814 1/20 0.64
NPSR1 Q6W5P4 5/20 0.56
HTT P42858 5/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
PAX8 Q06710 1/20 0.56
MMP14 P50281 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24130109 0.84 MEN1 (0.58) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL8745992 0.82 RAPGEF3 (0.52) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL24129811 0.82 MAPT (0.55) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL24130171 0.82 MAPT (0.55) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL924786 0.80 MAPT (0.60) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL2241345 0.79 ALDH1A1 (0.60) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL24130399 0.79 MAPT (0.55) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL345231 0.78 MAPT (1.00) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL3860882 0.78 MAPT (0.59) MAPTMEN1KMT2ATDP1ALDH1A1
SCHEMBL9422023 0.78 MAPT (0.62) MAPTMEN1KMT2ATDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112912069-A PPAR delta activators 国立研究开发法人科学技术振兴机构 2021-06-04 CN disclosed
CN-107865899-B Use of emblic leafflower fruit extract for preparing pharmaceutical composition for protecting mitochondria in retina 台湾粒线体应用技术股份有限公司 2021-03-05 CN disclosed
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 US disclosed
US-8445694-B2 Hydrazonopyrazole derivatives and their use as therapeutics DERMIRA (CANADA), INC. (US) 2013-05-21 US disclosed
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 US disclosed
US-7875728-B2 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death Valocor Therapeutics, Inc. (CA) 2011-01-25 US disclosed
US-7105503-B2 Pyrazole compounds QLT INC. (CA) 2006-09-12 US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US disclosed
EP-1450791-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Kinetek Pharmaceuticals, Inc. (CA) 2004-09-01 EP disclosed
WO-2003045379-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS KINETEK PHARMACEUTICALS, INC. (CA) 2003-06-05 WO disclosed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 US disclosed
EP-1276723-A2 PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY Kinetek Pharmaceuticals, Inc. (CA) 2003-01-22 EP disclosed
US-6436915-B1 ANTIPROLIFERATIVE AND ANTITUMOR AGENTS AND ANGIOGENESIS INHIBITORS KINETEK PHARMACEUTICALS, INC. (CA) 2002-08-20 US disclosed
US-20020042501-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2002-04-11 US disclosed
WO-2001077080-A2 PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY KINETEK PHARMACEUTICALS, INC. (CA) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 MAPT 4573/4885MEN1 3936/4885KMT2A 2931/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 MAPT 4573/4885MEN1 3936/4885KMT2A 2931/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC MAPT 4000/4885MEN1 1844/4885KMT2A 4148/4885
US-20030060453-A1 Pyrazole compounds CCNC, MKI67, CDC25C MAPT 4486/4885MEN1 3439/4885KMT2A 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.